Table 3.

Summary of adverse events in safety population. Values are numbers (percentages)

Adverse events*	SOC plus HCQ (n=70)	SOC (n=80)
Any adverse event	21 (30)	7 (9)
Serious adverse event	2 (3)	0
Disease progression	1 (1)	0
Upper respiratory tract infection	1 (1)	0
Non-serious adverse event	19 (27)	7 (9)
Diarrhoea	7 (10)	0
Vomiting	2 (3)	0
Nausea	1 (1)	0
Abdominal discomfort	1 (1)	0
Thirst	1 (1)	0
Abdominal bloating	0	1 (1)
Sinus bradycardia	1 (1)	0
Hypertension	1 (1)	0
Orthostatic hypotension	1 (1)	0
Hypertriglyceridaemia	1 (1)	0
Decreased appetite	1 (1)	0
Fatigue	1 (1)	0
Fever	0	1 (1)
Dyspnoea	1 (1)	0
Flush	1 (1)	0
Liver abnormality	0	1 (1)
Kidney injury	1 (1)	0
Coagulation dysfunction	1 (1)	0
Hepatic steatosis	0	1 (1)
Otitis externa	0	1 (1)
Blurred vision	1 (1)	0
Decreased white blood cells	1 (1)	0
Increased alanine aminotransferase	1 (1)	1 (1)
Increased serum amylase	1 (1)	0
Decreased neutrophil count	1 (1)	0
Increased serum amyloid A	0	1 (1)

HCQ=hydroxychloroquine; SOC=standard of care.

^*Multiple occurrences of same adverse event in one patient were counted.